BioNTech (BNTX) Competitors $111.80 +1.75 (+1.59%) As of 02:04 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BNTX vs. GSK, TAK, ARGX, ONC, TEVA, INSM, SMMT, ITCI, GMAB, and RDYShould you be buying BioNTech stock or one of its competitors? The main competitors of BioNTech include GSK (GSK), Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), Teva Pharmaceutical Industries (TEVA), Insmed (INSM), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry. BioNTech vs. Its Competitors GSK Takeda Pharmaceutical argenex BeOne Medicines Teva Pharmaceutical Industries Insmed Summit Therapeutics Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories BioNTech (NASDAQ:BNTX) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations. Which has more volatility and risk, BNTX or GSK? BioNTech has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500. Comparatively, GSK has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Does the media favor BNTX or GSK? In the previous week, GSK had 15 more articles in the media than BioNTech. MarketBeat recorded 16 mentions for GSK and 1 mentions for BioNTech. GSK's average media sentiment score of 0.87 beat BioNTech's score of 0.47 indicating that GSK is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GSK 9 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in BNTX or GSK? 15.5% of BioNTech shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 19.2% of BioNTech shares are owned by insiders. Comparatively, 10.0% of GSK shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is BNTX or GSK more profitable? GSK has a net margin of 9.89% compared to BioNTech's net margin of -27.37%. GSK's return on equity of 48.82% beat BioNTech's return on equity.Company Net Margins Return on Equity Return on Assets BioNTech-27.37% -3.94% -3.41% GSK 9.89%48.82%11.15% Do analysts recommend BNTX or GSK? BioNTech presently has a consensus price target of $137.86, indicating a potential upside of 23.31%. GSK has a consensus price target of $37.38, indicating a potential downside of 2.39%. Given BioNTech's stronger consensus rating and higher probable upside, equities analysts plainly believe BioNTech is more favorable than GSK.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioNTech 0 Sell rating(s) 4 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.83GSK 1 Sell rating(s) 7 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.11 Which has better valuation and earnings, BNTX or GSK? GSK has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioNTech$2.98B9.03-$719.92M-$3.40-32.88GSK$40.10B1.96$3.29B$1.9419.74 SummaryGSK beats BioNTech on 10 of the 16 factors compared between the two stocks. Get BioNTech News Delivered to You Automatically Sign up to receive the latest news and ratings for BNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BNTX vs. The Competition Export to ExcelMetricBioNTechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$26.88B$2.88B$5.46B$8.93BDividend YieldN/A2.44%5.24%4.04%P/E Ratio-32.8820.9427.0720.17Price / Sales9.03194.82381.5293.95Price / CashN/A41.7026.2128.59Price / Book1.287.518.015.59Net Income-$719.92M-$55.04M$3.17B$248.41M7 Day Performance3.99%5.25%3.53%6.17%1 Month Performance3.05%2.30%2.73%7.83%1 Year Performance38.90%5.33%34.10%21.03% BioNTech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BNTXBioNTech1.5101 of 5 stars$111.80+1.6%$137.86+23.3%+37.4%$26.88B$2.98B-32.886,772GSKGSK2.3525 of 5 stars$38.38-0.5%$37.38-2.6%-1.6%$78.58B$31.53B19.7890,100TAKTakeda Pharmaceutical1.2918 of 5 stars$15.46+2.4%N/A+14.1%$49.19B$30.09B70.2847,300ARGXargenex4.3873 of 5 stars$551.22-1.6%$729.93+32.4%+25.3%$33.66B$2.58B34.00650Analyst UpgradeHigh Trading VolumeONCBeOne Medicines2.9889 of 5 stars$242.07+0.4%$320.67+32.5%N/A$26.53B$3.81B-65.079,000TEVATeva Pharmaceutical Industries4.1993 of 5 stars$16.76flat$24.13+43.9%+2.7%$19.22B$16.54B-14.5736,800Positive NewsOptions VolumeINSMInsmed4.1249 of 5 stars$100.64+1.2%$106.80+6.1%+38.5%$19.09B$363.71M-16.91740Positive NewsAnalyst ForecastSMMTSummit Therapeutics2.4954 of 5 stars$21.28+3.3%$35.09+64.9%+212.3%$15.80B$700K-62.59110ITCIIntra-Cellular Therapies0.7441 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560News CoverageGMABGenmab A/S3.858 of 5 stars$20.66+0.8%$37.60+82.0%-19.7%$13.25B$3.12B11.742,682Analyst ForecastRDYDr. Reddy's Laboratories2.7149 of 5 stars$15.03-0.3%$16.95+12.8%-3.4%$12.55B$3.81B22.7727,811 Related Companies and Tools Related Companies GSK Competitors Takeda Pharmaceutical Competitors argenex Competitors BeOne Medicines Competitors Teva Pharmaceutical Industries Competitors Insmed Competitors Summit Therapeutics Competitors Intra-Cellular Therapies Competitors Genmab A/S Competitors Dr. Reddy's Laboratories Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BNTX) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredNobel Prize Material Finally Goes CommercialA Nobel Prize–winning material just got its biggest breakthrough in 30 years. A little-known company has cr...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioNTech SE Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share BioNTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.